Louisiana Residents File Lawsuit in Federal Court After Plaintiff Was Diagnosed With Breast Cancer After Taking The Weight Loss Drug Belviq.
On January 11, 2021, a couple residing in the State of Louisiana reportedly filed a Belviq breast cancer lawsuit in the United States District Court for the Western District of Louisiana (Shreveport Division), styled Maryann Kaylor and Willard Kaylor, Jr. v. Eisai, Inc., Eisai Co., Ltd., Arena Pharmaceuticals GmbH, and Arena Pharmaceuticals, Inc., Case No. 5:21-cv-00058 alleging, among other things, that the plaintiff used the diet drug Belviq beginning in or about September 2014 through March 2015 and subsquently suffered from breast cancer, having been diagnosed on or about January 14, 2020.
The Belviq breast cancer lawsuit reportedly alleges, among other things, that Defendants knew or should have known that Belviq had not been property tested, was not safe and/or was not effective for its indicated use. According to the Belviq complaint, the FDA issued a safety communication regarding clinical trial results showing a possible increased risk of cancer with Belviq.
The Belviq breast cancer case asserts personal injury claims against defendants for allegedly violating the Louisiana product liability act for inadequate warnings, breach of express warranty, design defect, manufacturing defect, and loss of consortium.
The Belviq breast cancer lawsuit complaint reportedly seeks an award of compensatory damages, including pain and suffering, mental anguish, disability, disfigurement, loss of ability to enjoy life, loss of ability to pursue happiness, and personality change, health care costs, medical monitoring, rehabilitation expenses, and interest and costs.
If you used Belviq (lorcaserin) and suffered from breast cancer, you might be eligible to recover compensation from a Belviq cancer lawsuit claim.
If You Have Thoughts On The Belviq Breast Cancer Lawsuit, Share Your Comments Below.